Contrôle génétique et mécanique de la fusion des myoblastes – MyoFuse
MyoFuse
Here, we will investigate the mechanisms whereby TGFß signaling exerts its inhibiting action on fusion and its possible interplay with cellular and environmental mechanical properties. In addition, we will determine whether mechanical constraints at the cell membrane and in the microenvironment mediate and/or synergize with cell-cell signaling to inhibit fusion in vertebrates.
In this project, we wished to investigate the mechanisms whereby TGFß signaling exerts its inhibiting action on fusion and its possible interplay with cellular and environmental mechanical properties. Functional analyses and live observation of cellular behaviors when the function of candidate genes is modulated, were to be performed. In addition, we wished to determine whether mechanical constraints at the cell membrane and in the microenvironment mediate and/or synergize with cell-cell signaling to inhibit fusion. Three aims were to be addressed: <br />Aim1. Combine biochemical and functional approaches in mouse and chicken to identify and characterize the downstream effectors of TGFß signaling. <br />Aim2. Perform dynamic analyses of fusion using live imaging in normal and mutant conditions. <br />Aim3. Explore the changes in mechanical properties of membranes and microenvironment during muscle fusion when TGFß signaling (or its effectors) is active or not.
During the first 18 months period, significant advances were made on the project.
The teams of FLG and BL developed a miniaturized 3D myotube culture chip with contraction monitoring capacity. This was done by using micropatterned substrate to grow primary myoblasts. Spontaneous contractions in myotubes derived from primary human myoblasts were observed. Analysis of nuclear morphology confirmed a similar organization between obtained myotubes and in vivo myofibers. LMNA-related Congenital Muscular Dystrophy (L-CMD) was modelled with mutant 3D myotubes displaying contractile dysfunction. This technology can thus be used to study contraction characteristics and evaluate how diseases affect muscle organization and force generation. Importantly, it requires significantly fewer starting materials than current systems, which should allow to substantially improve drug screening capability. A paper describing these data was recently submitted for publication (https://www.biorxiv.org/content/10.1101/2021.06.15.448543v3).
The teams of CM and BL have made significant advances in our understanding of the regulation of fusion by mechanical stress. Preliminary data they have obtained using traction force microscopy and live imaging shows that, in vitro, myoblast and myocyte fusion predominantly occurs in regions of increased environmental /cellular stress, which tightly correlate with singularities in cell alignments, also named nematic defects. The results of these analyses have been presented by CM at the Society for Muscle Biology «Frontiers in Myogenesis« International Conference in Costa Rica in November 2021. These results are important, as they show for the first time that mechanical stress (environmental / intra-tissular) could represent an underestimated regulator of myoblast fusion. These results need first to be confirmed. Translation of these results with in vivo context needs to be investigated and tested.
CM team is also investigating the role of putative TGF beta effectors in the regulation of fusion. These are ongoing experiments with no major breakthrough yet.
The experiments that were done during the first 18 months period are in line with the proposed experiments in the research project. Moreover, very significant advances were made in a short time, underlying the originality and high potential of this project
Publication par les équipes de F. Le Grand et B. Ladoux d'un article (Bioengineering a Miniaturized In Vitro 3D Myotube Contraction Monitoring Chip For Modelization of Muscular Dystrophies) pour le moment dans bioRxiv, soumis à Biomaterials.
Présentation par C. Marcelle des données issues de la collaboration CM/BL sur la mécanotransduction à un congrès international (Frontiers in Myogenesis Conference)
Publication par les équipes de F. Le Grand et B. Ladoux d'un article (Bioengineering a Miniaturized In Vitro 3D Myotube Contraction Monitoring Chip For Modelization of Muscular Dystrophies) pour le moment dans bioRxiv, soumis à Biomaterials.
Présentation par C. Marcelle des données issues de la collaboration CM/BL sur la mécanotransduction à un congrès international (Frontiers in Myogenesis Conference)
La fusion des myoblastes aux fibres musculaires est essentielle à la croissance et la réparation de muscles squelettiques. Des résultats préliminaires des groupes participants démontrent que la voie de signalisation TGFß (SMAD2/3-dependante) agit comme frein moléculaire de la fusion au cours du développement de l'embryon de poulet et lors de la régénération des muscles de la souris adulte. Cette voie de signalisation constitue donc le premier groupe de molécules agissant comme inhibiteurs de la fusion. De plus, le phénotype spectaculaire d'hyper-fusion observé quand cette voie est entravée indique que la modération du processus de fusion est un aspect étonnamment important de la formation et la réparation des muscles chez les vertébrés. Dans ce projet, nous identifierons les effecteurs intracellulaires (directs ou transcriptionnels) de la signalisation TGFß et nous testerons si des changements mécaniques à la membrane ou dans le micro environnement collaborent avec ces effecteurs pour réguler la fusion. De nombreuses techniques de pointe, comme l'imagerie in vivo de la fusion, la microscopie de force atomique, le micropatterning protéique et l'activation de voies de signalisation par l'optogénétique seront utilisées de manière innovante tout au long de ce project pour délivrer une vision unique de la fusion musculaire chez les vertébrés.
Coordination du projet
Christophe Marcelle (Institut Neuromyogène)
L'auteur de ce résumé est le coordinateur du projet, qui est responsable du contenu de ce résumé. L'ANR décline par conséquent toute responsabilité quant à son contenu.
Partenariat
INMG - CNRS Institut Neuromyogène
INMG Institut Neuromyogène
IJM Institut Jacques Monod
Aide de l'ANR 663 727 euros
Début et durée du projet scientifique :
septembre 2019
- 48 Mois